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Where there is conformity across the findings, interpretation and implications of ‘clinical’ and ‘economic’ research,
there is limited cause for concern. However, there is often unease when apparent contradictory conclusions are
drawn from the same study. Given the ever increasing role for economic evaluation in healthcare decision making,
this commentary challenges the necessity of compatibility between clinical and economic evaluation.
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With many countries requiring evidence of cost-effec-
tiveness prior to passing judgment on the value of a
medical intervention, it is inevitable that clinical and
economic evidence will be considered concurrently by
policy makers [1,2]. Such an approach enables decision
makers to reflect on scientific and social value judg-
ments (addressing both equity and efficiency) when allo-
cating scarce resources [3]. In circumstances where
there is conformity across the findings and implications
of clinical and economic research, few concerns are
raised. However, there is often unease when apparent
contradictory conclusions are drawn within a study, ei-
ther because the clinical research shows benefit but the
economics indicates that a therapeutically beneficial
intervention is not cost-effective [4,5], or the clinical re-
search shows little benefit but the economics reveals evi-
dence of cost-effectiveness for one of the interventions
being evaluated [6]. For example, a recent study reported
that a lifestyle program for adults at risk for type 2 dia-
betes and/or cardiovascular disease was not more effec-
tive in reducing these risks when compared to general
health brochures, although the intervention had a high
probability of being cost-effective [7].* Correspondence: david_whitehurst@sfu.ca
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distribution, and reproduction in any mediumThe former situation is a reflection of the unavoidable
need for healthcare decision-making within the con-
straints of a finite budget; sometimes, health benefits at-
tributable to an intervention may not be sufficient to
warrant associated increases in expenditure. Unease in
the latter situation relates, primarily, to the different
methods of analysis adopted in clinical and economic
evaluation. Differing opinions regarding the role of eco-
nomic evaluation alongside randomized controlled trials
(RCTs) with indeterminate clinical findings can result in
difficulties/delays in publishing economic evaluation re-
sults, irrespective of whether concerns are expressed
within the study team or during the peer-review pro-
cess. In this commentary, we challenge the necessity
of compatibility between clinical and economic trial-
based research.Clinical and economic evaluation: distinct
scientific paradigms
Thomas Kuhn, the American physicist and philosopher,
wrote extensively on the history of science and, in par-
ticular, on the notion of paradigms in science. Describing
a paradigm as ‘the entire constellation of beliefs, values,
techniques, and so on shared by the members of a given
community’ [8], Kuhn’s definition provides an ideal back-
drop to revisit current, widely-practiced clinical and eco-
nomic evaluative frameworks, that is, pragmatic RCTs and
trial-based cost-effectiveness analyses.
There are stark differences between clinical and eco-
nomic evaluation with respect to the purpose of researchd Central Ltd. This is an open access article distributed under the terms of the
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nique’). Differences in belief, in this context, exist in the
respective objectives of clinical intervention studies and
economic evaluation. The pragmatic RCT is conducted
to quantify the magnitude of some factor(s) of interest,
providing an estimate of effectiveness for an intervention
compared to an appropriate control group. The purpose
is to determine the ability of an intervention to improve
patient-level outcome(s) (or, in the case of noninferiority
trials, to test whether an intervention is not unaccept-
ably worse than a current procedure or treatment) and
the contribution of the research lies in the increased evi-
dence base for clinicians and researchers. Alternatively,
the purpose of cost-effectiveness analysis is to provide
decision-makers with evidence on the value of an in-
tervention, reflecting efficiency and equity [3]. This
evidence is then considered against competing claims
for healthcare resources across a multitude of medical
conditions.
Despite fundamental differences between clinical and
economic evaluation, the distinction is somewhat blurred
with respect to analytic methodologies, despite the avail-
ability of research methods and reporting guidelines for
trial-based economic analyses [9]. As an illustration, many
readers will have read or heard (or said) comments such
as, ‘economic analysis is only important if there is evidence
of clinical benefits.’ In our opinion, this is wholly inap-
propriate as a starting point for consideration of cost-
effectiveness. Demonstrable clinical benefit is not a
prerequisite for economic evaluation; large clinical bene-
fits may be too expensive, small clinical benefits may be
cost-effective and, dare we say, health decrements may be
associated with sufficient cost savings to warrant an inter-
vention becoming part of routine care. We use the words
'large' and 'small', as opposed to 'significant' and 'non-sig-
nificant', to emphasize the difference in analytic focus be-
tween conventional economic evaluation (estimation) and
clinical evaluation (inference), which has been discussed
elsewhere [9-12]. We return to the questionable use
of inferential statistics for economic evaluation in the
following section.
Given the different research objectives of RCTs and
economic evaluations, it is not surprising that differences
exist with regard to the measurement of patient-level
benefit (‘value’). Clinical relevance is the key determinant
when selecting the primary outcome in a clinical trial [13];
the chosen outcome measure is required to measure pa-
tients’ response to treatment, often focusing on a condi-
tion-specific measure of response that is meaningful to
the clinical community, with the results being interpret-
able at the individual patient level. However, the relevance
of the chosen clinical outcome measure is likely neg-
ligible when exploring the ‘economic’ consequences of
a particular intervention. For example, assessment ofcost-effectiveness within a cost-utility framework brings
together two components: costs (defined by the pers-
pective of the analysis) and quality-adjusted life years
(QALYs). The standard approach for estimating QALYs
provides for the incorporation of societal health state
values through the use of preference-based health-related
quality of life (HRQoL) measures [1,2].
The results of an economic evaluation only have
meaning in a comparative sense. Although clinical effect-
iveness can be explored within the boundaries of a single
study, value judgments regarding efficiency and equity
require consideration of other demands on healthcare
resources. The pursuit of this broader, societal objec-
tive - albeit with patient-level data - is a reflection
that society comprises individuals, and all individuals
are potential patients.
Confusing analytic conciliation
The health economics research community has provided
its own contribution to the evaluative confusion. In par-
ticular, with respect to the measurement of health bene-
fit, studies published in recent years have subjected
preference-based HRQoL measures to concepts that are
fundamentally inferential in nature; namely, the minim-
ally important difference (MID) and the noninferiority
margin [14-16].
The MID is ‘the smallest difference in score in the do-
main of interest which patients perceive as beneficial
and which would mandate, in the absence of trouble-
some side effects and excessive cost, a change in the pa-
tient’s management’ [17]. Although the concept of the
MID is well accepted in clinical research, we believe
there is some concern regarding its application for cost-
effectiveness research (despite a number of studies having
estimated MIDs for preference-based HRQoL instruments
[15,16]). MIDs, however defined, are specific to a single
outcome measure and are interpreted as being applicable
at a patient-level, meaning that the MID concept is too
narrow to be meaningful in economic evaluation. Cost-
effectiveness estimation requires the simultaneous con-
sideration of costs and effects. The magnitude of a cost
(effect) difference, viewed in isolation, holds limited value
until combined with the respective difference in effects
(costs). Just because it is possible to construct a minimally
important difference for preference-based measures does
not mean that it is useful.
Similar issues arise in relation to noninferiority trials
[14]. Guidelines for the conduct of economic evaluation
alongside such trials state that acceptable differences in
costs and effects must be defined a priori in order to
explore non-inferior or equivalent cost-effectiveness of
study treatments. However, these requirements take no
account of the key analytic focus of economic evalu-
ation: estimation of the joint density of cost and effect
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or QALY difference is ‘acceptable’ is not the role of the
analyst. In a trial-based economic evaluation, irrespective
of the clinical findings or RCT design (superiority, nonin-
feriority, or equivalence), an analyst should focus on esti-
mating cost and effect differences and quantifying the
likelihood that an intervention is cost-effective [9,12].
Conclusions
There is a need to understand better the fundamental
differences in the questions being addressed by clinical
and economic evaluation performed alongside RCTs,
and for all researchers to be comfortable with apparently
discordant findings. It is our hope that this commentary
will provide clarity, or spark further debate, and afford a
reference point for future discussions about ‘incompa-
tible’ RCT findings.
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